Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Marine Biomedical Pty Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit. The presence of only 1 distinct examiner for the 1 pending office action indicates a focused prosecution environment. This concentration suggests that the company is currently focusing its resources on a specific biotechnological or pharmaceutical innovation that is being evaluated within a single technical classification.
WAX, ROBERT A is the busiest examiner for this portfolio, currently managing 1 pending office action. Since there is only 1 distinct examiner, this individual is responsible for all active matters. The single pending office action within 1 distinct art unit suggests the company is pursuing a specific innovation that requires a targeted prosecution approach. For the applicant, this means that the entire current interaction with the patent office is concentrated on one examiner, making their specific feedback and examination style critical to the outcome of the application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18405569 | Method for Manufacturing a Calcified Tissue Substitute | WAX, ROBERT A | 27d |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18405569 | Method for Manufacturing a Calcified Tissue Substitute | WAX, ROBERT A | 1615 | §103§112 | Final Rejection | 27d | Pending | Jan 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMarine Biomedical Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert A Wax has the most, with 1 of Marine Biomedical Pty Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
